Investigation of Factors Influencing the Prognosis in Prostate Cancer Patients with Isolated Bone Metastasis

被引:0
|
作者
Ebinc, Senar [1 ]
Oruc, Zeynep [1 ]
Urakci, Zuhat [1 ]
Kaplan, Muhammet Ali [1 ]
Kucukoner, Mehmet [1 ]
Isikdogan, Abdurrahman [1 ]
机构
[1] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkey
来源
关键词
prostate prostate Bone metastasis; prostate cancer; prognostic factors; SURVIVAL; ANEMIA; MODEL; PROGRESSION; OUTCOMES; THERAPY; VOLUME; MEN;
D O I
10.4274/uob.galenos.2022.2022.1.4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Bone metastases, which show a milder course compared with visceral disease, are among the most common metastatic sites in prostate cancer. In the present study, we aimed to investigate the prognostic factors that influence the survival time in the castration-sensitive phase in patients diagnosed with prostate adenocarcinoma with isolated bone metastasis.Materials and Methods: The prognostic effects of the clinical (performance status, number of bone metastases) and laboratory parameters of a total of 217 patients, of whom the data could be accessed, on survival in the castration-sensitive phase were evaluated.Results: Of the 217 patients included in our study, 144 (66.4%) were metastatic at presentation. The mean age of the patients was 68.4 (42-88) years. The mean follow-up duration was 44 months. Of our 217 patients, 125 (57.6%) were included in the castration-sensitive group and 92 (42.4%) in the castration-resistant group. In multivariate analyses; lactate dehydrogenase, alkaline phosphatase (ALP) levels and the number of bone metastases were independent prognostic factors with a strong correlation with time to castration-resistant prostate cancer. The evaluation of these three parameters within the framework of a prognostic index and subsequent risk stratification revealed median progression-free survival times of 91, 36, 20 and 12 months for the very low-risk, low-risk, intermediate-risk and high-risk groups, respectively.Conclusion: Lactate dehydrogenase, ALP levels and the number of bone metastases were determined as strong and useful prognostic factors in predicting time to in
引用
收藏
页码:98 / 104
页数:7
相关论文
共 50 条
  • [21] A new nomogram for the prediction of bone metastasis in patients with prostate cancer
    Bai, Gang
    Cai, Zhonglin
    Zhai, Xiuxia
    Xiong, Jian
    Zhang, Fa
    Li, Hongjun
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (11)
  • [22] Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer
    Wolff, JM
    Bares, R
    Jung, PK
    Buell, U
    Jakse, G
    UROLOGIA INTERNATIONALIS, 1996, 56 (03) : 169 - 173
  • [23] Predicting Bone Metastasis in Prostate Cancer Patients: Value of Prostate Specific Antigen
    Wei, Ling-Huei
    Chiu, Jainn-Shiun
    Chang, Shiou-Ying
    Wang, Yuh-Feng
    TZU CHI MEDICAL JOURNAL, 2008, 20 (04): : 291 - 295
  • [24] Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis
    Vessella, Robert L.
    Corey, Eva
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6285S - 6290S
  • [25] An isolated pulmonary metastasis in prostate cancer
    Hofland, CA
    Bagg, MD
    MILITARY MEDICINE, 2000, 165 (12) : 973 - 974
  • [26] Isolated testicular prostate cancer metastasis
    Maibom, Sophia Liff
    Jacobsen, Andre
    Hansen, Rikke Bolling
    Brasso, Klaus
    SCANDINAVIAN JOURNAL OF UROLOGY, 2017, 51 (05) : 426 - 427
  • [27] Prognostic factors in endometrial cancer patients with bone metastasis
    Basarir, Zehra Ozturk
    Karaca, Mustafa Onur
    Balaban, Kamil
    Basarir, Kerem
    Yildiz, Huseyin Yusuf
    JOINT DISEASES AND RELATED SURGERY, 2023, 34 (01): : 207 - 214
  • [28] Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Yano, Masashi
    Endo, Takumi
    Takano, Makoto
    Komaru, Atsuhi
    Kawamura, Koji
    Sekita, Nobuyuki
    Imamoto, Takashi
    Ichikawa, Tomohiko
    UROLOGY, 2010, 75 (06) : 1446 - 1451
  • [29] HEALTH CARE COSTS IN PATIENTS WITH BONE METASTASIS SECONDARY TO PROSTATE CANCER COMPARED TO PROSTATE CANCER PATIENTS WITHOUT BONE METASTASIS IN THE OPTUM ONCOLOGY RESEARCH DATABASE
    Seal, B.
    Valderrama, A.
    Xia, F.
    Shermock, K. M.
    Asche, C.
    VALUE IN HEALTH, 2013, 16 (03) : A190 - A190
  • [30] Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer
    Nakajima, Kenichi
    Edenbrandt, Lars
    Mizokami, Atsushi
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (09) : 668 - 673